epirubicin has been researched along with Cancer, Second Primary in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (23.53) | 18.2507 |
| 2000's | 17 (50.00) | 29.6817 |
| 2010's | 9 (26.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Champagne, C; Gaillot-Petit, N; Guilbert, P; Lamberth, F; Looten-Vieren, L; Nguyen, TD | 1 |
| Amarillo, I; Fisher, SI; Rashidi, A | 1 |
| Angrilli, F; Baldini, L; Cascavilla, N; Federico, M; Ferrari, A; Galimberti, S; Gobbi, PG; Ilariucci, F; Luminari, S; Mammi, C; Marcheselli, L; Merli, F; Musso, M; Polimeno, G; Scalzulli, PR; Stelitano, C | 1 |
| Baubion, N; Buzyn, A; Decaudin, D; Delarue, R; Fourquet, A; Ghez, D; Hermine, O; Messas, E; Rubio, MT; Suarez, F; Varet, B; Willems, L | 1 |
| Byl, JA; Chang, C; Corser, R; Felix, CA; Grimwade, D; Hasan, SK; Hoyle, C; Lo-Coco, F; Mays, AN; Osheroff, N; Parker, AN; Peniket, A; Saravanamuttu, K; Solomon, E; Wiemels, JL; Xiao, Y | 1 |
| Altundag, K; Arslan, C; Dogan, E; Kara, O; Ozdemir, E | 1 |
| Ben Salah, H; Boudawara, T; Daoud, J; Frikha, M; Gargouri, R; Ghorbel, A; Ghorbel, L; Karray, H; Khabir, A; Toumi, N | 1 |
| Bliss, JM; Coleman, RE; Coombes, RC; Cooper, D; den Boer, MO; Erdkamp, F; Espie, M; Hupperets, P; Kilburn, LS; Marty, M; Reise, JA; Thomas, MW; Tres, A; Tubiana-Mathieu, N; Wals, J; Wardley, A; Wilkinson, K | 1 |
| Austin, CA; Cowell, IG | 1 |
| Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR | 1 |
| Anargyrou, K; Angelopoulou, MK; Boussiotis, VA; Boutsis, DE; Dimopoulou, MN; Karkantaris, C; Kokoris, SI; Kontopidou, FN; Kyrtsonis, MC; Michalopoulos, T; Panayiotidis, P; Pangalis, GA; Papavassiliou, C; Siakantaris, MP; Tsaftaridis, P; Variamis, E; Vassilakopoulos, TP | 1 |
| Bonneterre, J; Brémond, A; Chapelle-Marcillac, I; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Namer, M; Roché, H; Schraub, S | 1 |
| Alimonti, A; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Nardoni, C; Papaldo, P; Ruggeri, EM | 1 |
| Bonneterre, J; Campone, M; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P | 1 |
| Esfahani, F; Mehraban, D | 1 |
| Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P | 1 |
| Broglia, C; Cavanna, L; Chisesi, T; Corazza, GR; Corbella, F; Federico, M; Gobbi, PG; Iannitto, E; La Sala, A; Levis, A; Molica, S; Pavone, V; Sacchi, S; Valentino, F | 1 |
| Bertheault-Cvitkovic, F; Castèra, D; Combe, M; de la Lande, B; Demange, L; Garbay, JR; Graïc, Y; Krzisch, C; Leduc, B; Lucas, V; Mouret-Fourme, E; Nguyen, TD; Noguès, C; Rouëssé, J; Serin, D; Villet, R | 1 |
| Aleman, BM; Bosq, J; Carde, P; Dupouy, N; Eghbali, H; Girinsky, T; Hagenbeek, A; Henry-Amar, M; Kluin-Nelemans, JC; Krol, AD; Monconduit, M; Noordijk, EM; Pény, AM; Raemaekers, JM; Thomas, J; Tirelli, U; Verschueren, TA; Vovk, M | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Ha, SY; Lau, YL; Shek, TW | 1 |
| Cognetti, F; Ferretti, G; Papaldo, P | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Affolter, A; Ahmed, M; Marais, R; Nutting, CM; Pritchard-Jones, K; Sharma, AK; Thomas, V; Venkitaraman, R | 1 |
| Bonfante, V; Castellani, MR; Devizzi, L; Negretti, E; Santoro, A; Soncini, F; Villani, F; Viviani, S; Zanini, M; Zucali, R | 1 |
| Riggi, M; Riva, A | 1 |
| Marty, M | 1 |
| Hirabayashi, M; Nagai, T; Nishikori, M; Okamura, A; Tatsumi, E; Yokoi, M | 1 |
| Deguchi, S; Fujita, M; Honda, K; Kikuchi, T; Miyata, A | 1 |
| Ciarli, M; Laurenti, L; Leone, G; Menichella, G; Piccirillo, N; Salutari, P; Sica, S | 1 |
| Brugger, W; Engelhardt, R; Fetscher, S; Frommhold, H; Hasse, J; Kanz, L; Lange, W; Mertelsmann, R | 1 |
| Bliss, JM; Coombes, G; Coombes, RC; Fontaine, C; Marty, M; Morvan, F; Olmos, T; Pérez-López, FR; Vassilopoulos, P; Wils, JA; Woods, E | 1 |
| Arbona, C; Benet, I; Comes, AM; García Clavel, B; García-Conde, J; Lluch, A; Martínez-Climent, JA; Marugán, I; Prósper, F; Solano, C; Vizcarra, E | 1 |
| Mouridsen, HT | 1 |
4 review(s) available for epirubicin and Cancer, Second Primary
| Article | Year |
|---|---|
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Incidence; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Lymphatic Metastasis; Melphalan; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2003 |
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Incidence; Leukemia, Myeloid; Middle Aged; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Risk Factors; Stereoisomerism; Survival Rate | 2005 |
Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
Topics: Adenoma, Sweat Gland; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carcinoma, Acinar Cell; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Male; Mercaptopurine; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Parotid Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survivors; Sweat Gland Neoplasms; Vincristine; Whole-Body Irradiation | 2008 |
Rationale and use of epirubicin-based therapy in the adjuvant setting.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasms, Second Primary; Prognosis; Risk Factors | 2000 |
13 trial(s) available for epirubicin and Cancer, Second Primary
| Article | Year |
|---|---|
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Italy; Kaplan-Meier Estimate; Lomustine; Male; Melphalan; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2016 |
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Second Primary; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen; Taxoids | 2011 |
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart; Humans; Infusions, Intravenous; Middle Aged; Neoplasms, Second Primary; Prognosis | 2005 |
Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors | 2005 |
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Neoplasms, Second Primary; Postmenopause; Receptors, Estrogen; Retrospective Studies; Survival Rate; Tamoxifen | 2006 |
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Hodgkin Disease; Humans; Lomustine; Male; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Pilot Projects; Prednisone; Procarbazine; Survival Rate; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2006 |
A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiotherapy, Adjuvant | 2006 |
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2006 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Epirubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Prognosis; Risk Factors; Salvage Therapy; Vinblastine; Vincristine | 1994 |
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary | 1999 |
Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Female; Humans; London; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paris; Postmenopause; Proportional Hazards Models; Survival Rate; Tamoxifen | 1999 |
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart Diseases; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasms, Second Primary; Survival Rate | 2001 |
17 other study(ies) available for epirubicin and Cancer, Second Primary
| Article | Year |
|---|---|
[Potential indications for helical tomotherapy in breast cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Funnel Chest; Hodgkin Disease; Humans; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Obesity; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids | 2014 |
BRCA2-associated therapy-related acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Genes, BRCA2; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Taxoids | 2015 |
[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Daunorubicin; Epirubicin; Female; Fluorouracil; Heart Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Neoplasms, Second Primary; Remission Induction; Stroke Volume | 2010 |
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; DNA Damage; DNA Topoisomerases, Type II; Epirubicin; Female; Humans; Introns; Leukemia, Promyelocytic, Acute; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Nuclear Proteins; Promyelocytic Leukemia Protein; Quantitative Trait Loci; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic; Tumor Suppressor Proteins | 2010 |
Acute promyelocytic leukemia in a young patient with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiotherapy; Treatment Outcome | 2011 |
[Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Child; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioisotope Teletherapy; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Xerostomia; Young Adult | 2010 |
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Topics: Anthracyclines; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Humans; Leukemia; Mitoxantrone; Models, Genetic; Neoplasms, Second Primary; Poly-ADP-Ribose Binding Proteins; Translocation, Genetic | 2012 |
Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prednisone; Procarbazine; Prognosis; Radiotherapy Dosage; Recurrence; Remission Induction; Treatment Outcome; Vinblastine; Vincristine | 2004 |
Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Clinical Trials, Phase III as Topic; Epirubicin; Humans; Mathematical Computing; Multicenter Studies as Topic; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Reproducibility of Results; Sample Size; Urinary Bladder Neoplasms | 2005 |
Lineage-specific hematopoietic growth factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Neoplasms, Second Primary | 2006 |
Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Dactinomycin; DNA, Neoplasm; Epirubicin; Etoposide; Humans; Ifosfamide; Infant; Iodine Radioisotopes; Male; Neoplasms, Second Primary; Rhabdomyosarcoma, Embryonal; Spinal Neoplasms; Thoracic Vertebrae; Thyroid Neoplasms; Thyroidectomy; Vincristine | 2008 |
Therapy-related leukemia: what is the role of 4-epi-doxorubicin?
Topics: Epirubicin; Humans; Leukemia; Neoplasms, Second Primary | 1993 |
Epirubicin and the risk of leukemia: not substantiated? International Collaborative Cancer Group Steering Committee.
Topics: Epirubicin; Humans; Leukemia; Neoplasms, Second Primary | 1993 |
[Malignant lymphoma following operation and chemotherapy of small cell lung carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Pneumonectomy; Prednisolone; Remission Induction; Vincristine | 1993 |
[Therapy-related AML(M2) with t(8;21) that developed three years after chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Doxorubicin; Epirubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Translocation, Genetic | 1996 |
Secondary leukemia after autologous peripheral blood progenitor cell transplantation for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 1997 |
Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Postmenopause; Predictive Value of Tests; Premenopause; Transplantation, Autologous | 2000 |